NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin.
Li DJ, Sun SJ, Fu JT, Ouyang SX, Zhao QJ, Su L, Ji QX, Sun DY, Zhu JH, Zhang GY, Ma JW, Lan XT, Zhao Y, Tong J, Li GQ, Shen FM, Wang P.
Li DJ, et al. Among authors: sun dy, sun sj.
Theranostics. 2021 Feb 25;11(9):4381-4402. doi: 10.7150/thno.53652. eCollection 2021.
Theranostics. 2021.
PMID: 33754067
Free PMC article.